Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience

BACKGROUND: KRAS is the most frequently encountered driver mutation in advanced non-small cell lung cancer (NSCLC). With targeted therapy for the most common KRAS mutation p.G12C on the horizon, the aim of this study is to retrospectively report outcomes in patients with KRAS mutated NSCLC. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Ethan A., Ensor, Joe E., Hsu, Jim, Thomas, Jessica S., Olsen, Randall J., Bernicker, Eric H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411128/
https://www.ncbi.nlm.nih.gov/pubmed/34527319
http://dx.doi.org/10.21037/jtd-21-432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411128/
https://www.ncbi.nlm.nih.gov/pubmed/34527319
http://dx.doi.org/10.21037/jtd-21-432

Ejemplares similares